Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trial

The Lancet Infectious Diseases · Elsevier

Аннотация

Publication date: November 2026 Source: The Lancet Infectious Diseases, Volume 26, Issue 11 Author(s): Hong-Xing Pan, Zhao-Feng Bi, Yu-Lin Jing, Shang-Ying Hu, Li Zhang, Kong-Xin Zhu, Kai Chu, Ying Hong, Shu-Fang Chang, Qin-Jing Pan, Xun Zhang, Jin-Bo Xu, Jie Tang, Dong-Ya Yuan, Hui Jiang, Chao Du, Guang Sun, Guo-Hua Zhong, Qi Chen, Li-Hui Wei

Читать у издателя →

Похожие статьи